310 likes | 601 Views
TB Diagnosis. Caroline Wightman TB Clinical Nurse Specialist The Hillingdon Hospital. NW London TB rates per 100,000. TB in Hillingdon – Aug 2008. TB in NW London by Ethnic Group. TB in Hillingdon by Ethnic Group. TB in Hillingdon by Age and Sex.
E N D
TB Diagnosis Caroline Wightman TB Clinical Nurse Specialist The Hillingdon Hospital
Summary of Some TB Statistics for NW London in 2008 • 1111 reported cases • The overall TB incident rate 60.2 per 100,000 population • Brent had highest rate 113.7 • Westminster had lowest rate 29.9 • Hillingdon had rate of 61.0 (153 cases) a 20.4% increase from 2007 (127 cases) • Ethnic groups • Indian 38% (424 cases) • Black African 27% with 50% from Somalia
Summary of Some TB Statistics for NW London in 2008 (cont.) • 86% (956 cases) born abroad, 51% (341 cases) entered UK within last 5 yrs. • 49% of all cases in NWL in 2008 were pulmonary, of which 31% were sputum smear positive • Multi Drug Resistant TB was identified in 1.3% of cases tested
Signs and Symptoms • Cough (with or without haemoptysis) for more than 3 weeks • Most patients report cough for 2 – 3 months • Fevers / temperature (low grade) • Night sweats • Weight loss • Lethargy
Medical History • History of past TB • When • Length of treatment • Medication used • Past history of TB exposure • Place of birth/ how long in UK • 86% of TB patients born abroad • 51% of TB patients entered the UK < 5 years
Medical History (cont.) • Other chronic medical conditions • Diabetes • Alcohol dependence • Any immunodeficient conditions • HIV infection • History of BCG? • History of recent travel
Physical examination • To assess patient’s general health • Lymph nodes • Cervical, axilla, groin, sub-clavicular • Examination of affected area • Erythema induratum / nodosum
Investigations - Respiratory TB • CXR if suspicious for TB should initiate further investigations
Investigations - Respiratory TB (cont.) • Multiple sputum samples for AAFB and culture (acid alcohol fast bacilli) • Minimum of 3 (including 1 early morning) • Examine Film/ smear under microscopy on slide • Concentrate sample (auramine) positive = infectious TB • Liquid culture up to 8 weeks or more
Investigations(cont.) Microscopy = pot. infectious TB Ref Lab Concentrate ID & Sensitivities Culture Ref Lab 8 weeks
Investigations Adults Productive cough • spontaneous sputum Dry cough/ unable to produce sputum • bronchial lavage • induced sputum Children Productive cough • spontaneous sputum Unable to expectorate • Induced sputum (nebulised saline) • Gastric aspirates (early morning via NG tube)
Management of Respiratory TB • Treatment should start before culture results are available if clinical picture is consistent with TB • Standard treatment should continue even when culture results are negative • Samples should be sent for culture from autopsy if respiratory TB was suspected
Investigations - Non-Respiratory TB • Discuss advantages / disadvantages of biopsy and needle aspiration • Samples for TB culture (dry pot) • Lymph node biopsy • Pus aspirated from lymph nodes • Pleural biopsy • Any surgical sample sent for routine culture • Any radiological sample sent for routine culture • Histology sample • Aspiration sample • Autopsy sample
Management of Non- Respiratory TB • Treatment should be started without waiting for culture results if clinical / histological picture consistent with TB • Chest X-ray to exclude co-existing respiratory TB • Continue drug regimen even if culture results are negative
Other Diagnostic Aids Diagnostic Molecular Tests • PCR (polymerase chain reaction) detects & amplifies presence of DNA unique to specific organisms • Detects mutations to Rifampicin • Used for rapid confirmation of TB diagnosis in sputum smear positive cases that would alter their care or • Before conducting large contact tracing initiatives • Used infrequently as expensive • Negative PCR does not rule out TB diagnosis
Other Investigations (cont.) • Mantoux test (purified protein derivative) - 2 Tuberculin units by Intradermal injection - Measured 48 to 72 hours - Requires 2 visits - Skilled operator • Main use – contact and new entrant screening • Confounded by BCG vaccine, other Mycobacterium, viral illness, HIV • Negative Mantoux may rule out Sarcoid
IFN-γ release assays (IGRA) • ex-vivo immune assay • Previously sensitised T cells exposed to MTb antigens • measure release of IFN-γ
IGRA • Advantages : • Single visit • Objective • Incorporate controls • Potentially faster • Big advantage: choice of antigen…
RD1 contains the genes for ESAT6 and CFP10 M. bovis M. tuberculosis RD1 was lost from BCG early on RD1 is present in all strains of M. tuberculosis BCG BCG ESAT6-early secretory antigen target 6, CFP10 –culture filtrate protein 10
Quantiferon Gold In-Tube 1. Take blood into pre-coated tubes (nil, TB antigen, PHA positive control) 2. Incubate at 37°C for 16-24 hours 3. Centrifuge (15mins, 3000G ~ 3729rpm) 4. Harvest supernatant – can now be stored 5. ELISA at your leisure
Summary: IGRAs in Diagnosis • Overall in active disease both IGRAs are more sensitive than TST • Overall in LTBI TSPOT is more sensitive than TST, and QFN is as sensitive as TST • IGRAs are more specific than TST
Uses of IGRA • IGRA cannot distinguish between active and LTBI • May increase confidence in diagnosis if unable to isolate M.Tb from clinical specimens • False negatives can occur in immunosuppression • Expensive • NICE 2006 suggests 2-step testing with TST in contact tracing, new entrant screening & before immunosuppressive treatment (anti-TNF)
Conclusion – Think TB • Keep a high index of suspicion • Un-resolving cough • Chronic symptoms (back pain) • Recently arrived in UK from endemic countries - esp. Somalia • Early request for sputum / CXR • If in doubt refer
References • Health Protection Agency www.hpa.org.uk • Tuberculosis in the UK, Annual Report on Tuberculosis Surveillance in the UK 2008. HPA October 2008. • Tuberculosis in North West London. 2008 Annual Report. Health Protection Agency. • NICE TB Guidance. Clinical Diagnosis and management of Tuberculosis, and measures for its prevention and control. March 2006. • Image source: Core Curriculum on Tuberculosis - What the Clinician Should Know. 4th ed. 2000. Division of Tuberculosis Elimination, US Centres for Disease Control and Prevention (CDC)